Awakn Life Sciences: Key Patent Filed Covering Behavioral Addictions With Ketamine And Ketamine-Assisted Therapy May 27, 2022
Awakn Life Sciences CEO, Anthony Tennyson, Joins Dustin Robinson of Iter Investments for ‘The Investor… May 24, 2022
Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments Mar 17, 2022
Awakn CEO Anthony Tennyson Predicts 2022 Will Be A Big Year For Institutional Investment In Psychedelics Dec 9, 2021
CEOs Kelsey Ramsden and Anthony Tennyson Talk Psychedelic Partnerships: “Further, Faster, Together” Nov 16, 2021
MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across… Oct 28, 2021
Awakn Life Sciences: Re-Imagining Novel Therapeutic Solutions For Substance Use Disorders Oct 15, 2021
